Register for New Oral Anticoagulants (NOAC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01588119 |
Recruitment Status
:
Recruiting
First Posted
: April 30, 2012
Last Update Posted
: January 20, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Anticoagulation Treatment |
Study Type : | Observational |
Estimated Enrollment : | 3500 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Prospective Register Study to Record Safety and Efficacy of New Oral Anticoagulants |
Study Start Date : | November 2011 |
Estimated Primary Completion Date : | December 2018 |
Estimated Study Completion Date : | December 2018 |

Group/Cohort |
---|
Dabigatran
in atrial fibrillation
|
Rivaroxaban
in atrial fibrillation and VTE
|
Apixaban
in atrial fibrillation and VTE
|
Edoxaban
in atrial fibrillation
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- indication for treatment with long term anticoagulation
- initial adjustment or change to nex oral anticoagulant within routine treatment
- indication for treatment with long term anticoagulation within the register:
- permanent anticoagulation in arterial fibrillation
- intended anticoagulation in acute venous thromboembolism for min. 3 months
- other anticoagulation for min. 3 months within the approved indication
Exclusion Criteria:
- missing Informed Consent Form
- missing phone number for telephone follow up
- contraindication for therapy with new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) according to Summary of Product Characteristics

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01588119
Contact: Jan Beyer-Westendorf, MD | +49 351 458 ext 3659 | jan.beyer@uniklinikum-dresden.de |
Germany | |
Universitätsklinikum Dresden on behalf of GWT-TUD GmbH | Recruiting |
Dresden, Germany, 01307 | |
Contact: Jan Beyer-Westendorf, MD 0049 0351 458 ext 3659 jan.beyer@uniklinikum-dresden.de | |
Principal Investigator: Jan Beyer-Westendorf, MD |
Principal Investigator: | Jan Beyer-Westendorf, MD | study site at Universitätsklinikum Dresden on behalf of GWT-TUD GmbH |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | GWT-TUD GmbH |
ClinicalTrials.gov Identifier: | NCT01588119 History of Changes |
Other Study ID Numbers: |
NOAC |
First Posted: | April 30, 2012 Key Record Dates |
Last Update Posted: | January 20, 2017 |
Last Verified: | August 2016 |
Additional relevant MeSH terms:
Anticoagulants |